



Article

Verbascoside Elicits Its Beneficial Effects by Enhancing Mitochondrial Spare Respiratory Capacity and the Nrf2/HO-1 Mediated Antioxidant System in a Murine Skeletal Muscle Cell Line

Francesca Sciandra ¹, Patrizia Bottoni ^{2,*}, Marinella De Leo ³, Alessandra Braca ³, Andrea Brancaccio ^{1,4} and Manuela Bozzi ^{1,2,*}

¹ Istituto di Scienze e Tecnologie Chimiche “Giulio Natta”—SCITEC Sede di Roma, Largo F. Vito, 00168 Roma, Italy

² Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Sezione di Biochimica, Università Cattolica del Sacro Cuore di Roma, Largo F. Vito 1, 00168 Roma, Italy

³ Dipartimento di Farmacia, Università di Pisa, Via Bonanno 33, 56126 Pisa, Italy

⁴ School of Biochemistry, University of Bristol, Bristol BS8 1TD, UK

* Correspondence: patrizia.bottoni@unicatt.it (P.B.); manuela.bozzi@unicatt.it (M.B.)

Abstract: Muscle weakness and muscle loss characterize many physio-pathological conditions, including sarcopenia and many forms of muscular dystrophy, which are often also associated with mitochondrial dysfunction. Verbascoside, a phenylethanoid glycoside of plant origin, also named acteoside, has shown strong antioxidant and anti-fatigue activity in different animal models, but the molecular mechanisms underlying these effects are not completely understood. This study aimed to investigate the influence of verbascoside on mitochondrial function and its protective role against H₂O₂-induced oxidative damage in murine C2C12 myoblasts and myotubes pre-treated with verbascoside for 24 h and exposed to H₂O₂. We examined the effects of verbascoside on cell viability, intracellular reactive oxygen species (ROS) production and mitochondrial function through high-resolution respirometry. Moreover, we verified whether verbascoside was able to stimulate nuclear factor erythroid 2-related factor (Nrf2) activity through Western blotting and confocal fluorescence microscopy, and to modulate the transcription of its target genes, such as heme oxygenase-1 (HO-1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α), by Real Time PCR. We found that verbascoside (1) improved mitochondrial function by increasing mitochondrial spare respiratory capacity; (2) mitigated the decrease in cell viability induced by H₂O₂ and reduced ROS levels; (3) promoted the phosphorylation of Nrf2 and its nuclear translocation; (4) increased the transcription levels of HO-1 and, in myoblasts but not in myotubes, those of PGC-1 α . These findings contribute to explaining verbascoside's ability to relieve muscular fatigue and could have positive repercussions for the development of therapies aimed at counteracting muscle weakness and mitochondrial dysfunction.

Keywords: mitochondria; spare respiratory capacity; skeletal muscle; verbascoside; acteoside; heme oxygenase-1 (HO-1); peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α); nuclear factor erythroid 2-related factor (Nrf2); antioxidant response



Citation: Sciandra, F.; Bottoni, P.; De Leo, M.; Braca, A.; Brancaccio, A.; Bozzi, M. Verbascoside Elicits Its Beneficial Effects by Enhancing Mitochondrial Spare Respiratory Capacity and the Nrf2/HO-1 Mediated Antioxidant System in a Murine Skeletal Muscle Cell Line. *Int. J. Mol. Sci.* **2023**, *24*, 15276. <https://doi.org/10.3390/ijms242015276>

Academic Editors: Giorgio Fanò-Illic, Massimo Reconditi and Rosa Mancinelli

Received: 8 September 2023

Revised: 11 October 2023

Accepted: 16 October 2023

Published: 17 October 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

The skeletal muscle is one of the most energy-demanding tissues, since it must sustain continuous cycles of contraction and relaxation. Albeit to different extents, depending on the composition of the different muscle fiber types, all types of muscle acquire most of their ATP molecules from oxidative phosphorylation, occurring in the mitochondria. In this process, electron carriers, embedded within the inner mitochondrial membrane, transfer electrons from FADH₂ or NADH to O₂, in order to produce ATP through the action of

the ATP synthase complex. During this redox reaction, a small amount of O₂ may escape from its complete reduction to H₂O, forming reactive oxygen species (ROS), especially the superoxide anion (O₂^{•-}), which represent by-products of oxidative phosphorylation. Eukaryotic cells have many enzymes capable of scavenging ROS. For example, the enzyme superoxide dismutase removes the superoxide anion, transforming it into the less reactive and milder oxidant H₂O₂. This latter is still able to cross bi-layered biological membranes, producing oxidative damage to different cellular components, including DNA, proteins and lipids, also within the mitochondria. During exercise, the increased energy demand leads to increased oxygen consumption and consequently to the increased production of ROS. It has been demonstrated that a “physiological amount” of ROS is required to trigger an adaptive response to exercise—for example, by activating nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that targets many genes involved in the cellular response against oxidative stress and inflammation [1–4]. Oxidative damage occurs when ROS production overcomes the scavenging capacity of the antioxidant cellular defenses. ROS accumulation produces mitochondrial damage, resulting in the further increased release of ROS during oxidative respiration. This induces a vicious cycle, which is often associated with mitochondrial dysfunction, leading to muscle loss and muscle weakness, observed in many pathophysiological conditions, including aging-related sarcopenia [5], Duchenne muscular dystrophy [6] and numerous types of myopathies [7,8].

Healthy mitochondria modulate their metabolism in order to maintain proper energy levels inside the cells in different circumstances. Spare respiratory capacity (SRC) represents a functional parameter related to the ability of mitochondria to meet the growing energy needs of the cells when they are subjected to extra work or stressful conditions. Furthermore, SRC reflects the flexibility of cellular metabolism during complex and highly energy-demanding physiological processes, such as cell proliferation, differentiation and apoptosis [9]. A strong reduction in SRC was observed in mdx mice, a model for Duchenne muscular dystrophy [10,11], and in aging [12]. Interestingly, restoration of mitochondrial function alleviates the dystrophic symptoms in mdx mice [13,14].

Verbascoside is a phenylethanoid glycoside, largely found in dicotyledonous plants, which displays significant free-radical-scavenging activity in different cell and animal models [15–17]. Verbascoside was proven to increase resistance to fatigue in healthy animal models [18,19] and in mice with induced cachexia, by promoting the removal of dysfunctional mitochondria [20]. In light of these observations, we postulated that verbascoside ameliorates the mitochondrial function in C2C12 cells, which represent a well-established model of skeletal muscle. In order to verify this hypothesis, we evaluated the oxygen consumption rates of murine C2C12 cells, pre-treated with verbascoside, under normal and oxidative conditions, through high-resolution respirometry. In the present study, we also investigated (i) the protective role of verbascoside against oxidative stress induced by H₂O₂, (ii) a possible correlation between the protective role of verbascoside and Nrf2 activation and (iii) the effects of verbascoside on the transcriptional levels of the antioxidative enzyme heme oxygenase-1 (HO-1) and the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), which induces mitochondriogenesis. A deeper comprehension of the molecular mechanisms underlying the beneficial effects elicited by verbascoside on muscles could pave the way for the possible pharmacological use of verbascoside in all physio-pathological conditions characterized by muscle weakness and mitochondrial dysfunction.

2. Results

2.1. Verbascoside Improved Mitochondrial Spare Respiratory Capacity

In order to investigate the effects of verbascoside on the mitochondrial respiratory function of C2C12 myoblasts and myotubes, we first established a safe working concentration of verbascoside on the basis of a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay performed by treating cells with increasing verbascoside concentrations for 24 h. We opted for a 24 h treatment, since it has been shown that the concentration

of a 320 μM verbascoside aqueous solution at pH 7 decreases to 62% after 24 h due to degradation [21]. Verbascoside did not alter C2C12 myotubes' viability at up to 300 μM , whereas a cytotoxic effect at concentration values equal to or greater than 250 μM was observed on C2C12 myoblasts (Figure 1). Therefore, a concentration of 150 μM was used for the subsequent experiments.




Figure 1. Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tests. C2C12 myoblasts were treated with increasing concentrations of verbascoside for 24 h. Data are reported as mean percentage values \pm SD relative to control (100%) of three independent experiments performed in duplicate. Statistical analysis was performed using Student's *t*-test (** $p \leq 0.01$, *** $p \leq 0.001$, verbascoside-treated cells vs. untreated cells).

To assess verbascoside's effects on the respiratory capacity of C2C12 myoblasts and myotubes, high-resolution respiratory (HRR) measurements were carried out on treated and untreated cells, simultaneously, upon the sequential addition of pharmacologic inhibitors of oxidative phosphorylation, such as oligomycin (2.5 μM), uncoupler carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 0.05 μM), rotenone (0.5 μM) and antimycin A (2.5 μM). HRR measures, displayed as oxygen flux per cell number, revealed no significant changes in basal oxygen consumption rate (OCR) in both C2C12 myoblasts and myotubes, following verbascoside treatment (Figure 2A,B and Table 1). Similarly, oligomycin-sensitive respiration (proton leak), which is induced by inhibiting ATP synthase with oligomycin and corresponds to resting, non-phosphorylating electron transfer, was not influenced by verbascoside, indicating no alterations of the inner mitochondrial membrane's integrity or associated proton transport (Figure 2A,B and Table 1). Notably, the level of maximal uncoupled respiratory activity (maximal OCR), recorded in the presence of optimal uncoupler (FCCP) concentrations, was positively influenced by verbascoside in both C2C12 myoblasts and myotubes. This parameter, which is a measure of the functionality of the mitochondrial respiratory system and is independent of the cellular energy demand, was significantly increased by about 27% and 13% in myoblasts and myotubes, respectively, compared to untreated cells (Figure 2A,B and Table 1). Lastly, the evaluation of residual OCR, measured upon the addition of rotenone and antimycin A, which are inhibitors of Complex I and Complex III, respectively, revealed that verbascoside did not change the non-mitochondrial oxygen-consuming processes, for both myoblasts and myotubes (Figure 2A,B and Table 1).

The flux control ratios derived from HRR measures are useful indicators of mitochondrial function as they are internally normalized to the overall number of cells and allow the accurate comparison of treated and untreated cells [22]. Among them, the spare respiratory capacity (SRC), which represents a robust functional parameter to evaluate mitochondrial reserve capacity, was significantly increased by about 51% and 13% in verbascoside-treated myoblasts and myotubes, respectively, compared to untreated cells (Figure 2C,D and Table 2). No differences were reported for the coupling efficiency (CE) and respiratory control ratio (RCR) for both C2C12 myoblasts and myotubes (Table 2).




Figure 2. Cont.




Figure 2. High-resolution respirometry measurements carried out on C2C12 myoblasts (A) and myotubes (B) treated with 150 μM verbascoside for 24 h. Basal oxygen consumption rate (OCR), proton leak, maximal OCR and non-mitochondrial respiration (residual OCR) are expressed as [$\text{pmol}/(\text{s} \times 10^6)$] and are average values \pm SD of four independent experiments performed in duplicate. The OCR obtained after addition of 0.5 μM rotenone and 2.5 μM antimycin A (residual OCR) was subtracted from all other OCRs. Statistical analysis was performed using Student's *t*-test (* $p \leq 0.05$, ** $p \leq 0.01$). The spare respiratory capacity (SRC) was calculated as the ratio between maximal OCR and basal OCR and is reported as mean \pm SD value of four independent experiments performed in duplicate on C2C12 myoblasts (C) and myotubes (D). Statistical analysis was performed using Student's *t*-test (* $p \leq 0.05$, ** $p \leq 0.01$).

Table 1. Oxygen consumption rates (OCR) are expressed as [$\text{pmol}/(\text{s} \times 10^6)$] and are average values \pm SD from four independent experiments performed in duplicate on C2C12 myoblasts and myotubes. Statistical analysis was performed using Student's *t*-test (* $p \leq 0.05$, ** $p \leq 0.01$, verbascoside-treated (+V) vs. untreated cells (−V)).

Myoblasts	OCR ($\text{pmol}/(\text{s} \times 10^6)$) −V	OCR ($\text{pmol}/(\text{s} \times 10^6)$) +V	OCR ($\text{pmol}/(\text{s} \times 10^6)$) −V/+H ₂ O ₂	OCR ($\text{pmol}/(\text{s} \times 10^6)$) +V/+H ₂ O ₂
Basal OCR	34.7 \pm 4.7	34.1 \pm 3.5	19.9 \pm 2.3	19.0 \pm 2.3
Proton Leak	12.6 \pm 1.4	14.01 \pm 0.99	9.1 \pm 1.2	11.5 \pm 1.4
Maximal OCR	59.6 \pm 10.3	75.7 \pm 8.9 **	23.1 \pm 3.3	41.0 \pm 5.6 **
Residual OCR	5.10 \pm 0.69	6.03 \pm 0.77	6.77 \pm 0.56	5.93 \pm 1.08

Table 1. Cont.


Myotubes	OCR ($\text{pmol}/(\text{s} \times 10^6)$ –V)	OCR ($\text{pmol}/(\text{s} \times 10^6)$ +V)	OCR ($\text{pmol}/(\text{s} \times 10^6)$ –V/+H ₂ O ₂)	OCR ($\text{pmol}/(\text{s} \times 10^6)$ +V/+H ₂ O ₂)
Basal OCR	38.0 ± 5.5	36.5 ± 2.3	30.9 ± 0.2	25.3 ± 2.5
Proton Leak	8.6 ± 1.1	9.6 ± 1.6	9.9 ± 1.1	8.0 ± 1.9
Maximal OCR	140.1 ± 13.6	158.6 ± 18.1 *	69.8 ± 6.6	87.3 ± 5.7 *
Residual OCR	6.0 ± 2.1	6.3 ± 1.1	5.8 ± 0.6	5.6 ± 1.0

Table 2. Flux control ratios derived from high-resolution respiratory measures are reported as average values ± SD from four independent experiments performed in duplicate on C2C12 myoblasts and myotubes. Statistical analysis was performed using Student's *t*-test (* $p \leq 0.05$, ** $p \leq 0.01$; verbascoside-treated (+V) vs. untreated cells (–V)).

Myoblasts	–V	+V	–V/+H ₂ O ₂	+V/+H ₂ O ₂
SRC	1.72 ± 0.15	2.60 ± 0.22 **	1.60 ± 0.20	2.14 ± 0.08 *
RCR	5.33 ± 0.59	5.53 ± 0.78	3.24 ± 0.17	4.11 ± 0.54
CE	0.61 ± 0.05	0.57 ± 0.07	0.53 ± 0.06	0.50 ± 0.02
Myotubes	–V	+V	–V/+H ₂ O ₂	+V/+H ₂ O ₂
SRC	3.8 ± 0.3	4.3 ± 0.3 *	2.24 ± 0.2	3.6 ± 0.2 *
RCR	16.5 ± 1.0	16.9 ± 1.1	7.0 ± 0.3	11.6 ± 1.6 *
CE	0.76 ± 0.03	0.78 ± 0.005	0.67 ± 0.04	0.77 ± 0.04

2.2. Verbascoside Partially Restored Mitochondrial Function under Oxidative Conditions

The high-resolution respiratory (HRR) measurements carried out on C2C12 myoblasts and myotubes exposed to oxidative stress revealed that H₂O₂ treatment strongly reduced the basal and maximal oxygen consumption rates (OCR), whereas proton leak was slightly reduced in myoblasts and unaltered in myotubes (Table 1). Oxidative conditions did not significantly change the residual OCR, which was due to non-mitochondrial respiration (Table 1). Verbascoside did not rescue the basal OCR, but partially restored the maximal OCR, increasing its values by about 77% in myoblasts and 25% in myotubes, and the spare respiratory capacity (SRC), increasing its values by about 34% in myoblasts and 61% in myotubes, confirming a protective role against oxidative damage (Figure 3, Tables 1 and 2). In myotubes, verbascoside also restored the RCR by about 66%, indicating greater potential for substrate oxidation and ATP turnover (Table 2).

**Figure 3.** Cont.




Figure 3. High-resolution respirometry measurements carried out on C2C12 myoblasts (A) and myotubes (B) pre-treated with 150 μ M verbascoside for 24 h and exposed to 0.5 mM H₂O₂ for 1 h. Basal oxygen consumption rate (OCR), proton leak, maximal OCR and non-mitochondrial respiration (residual OCR) are expressed as [pmol/(s \times 10⁶)] and are average values \pm SD of four independent experiments performed in duplicate. The oxygen consumption rate obtained after addition of 0.5 μ M rotenone and 2.5 μ M antimycin A (residual OCR) was subtracted from all other OCRs. Statistical analysis was performed using Student's *t*-test (* $p \leq 0.05$, ** $p \leq 0.01$). The spare respiratory capacity (SRC) was calculated as the ratio between maximal OCR and basal OCR and is reported as mean \pm SD value of four independent experiments performed in duplicate on C2C12 myoblasts (C) and myotubes (D). Statistical analysis was performed using Student's *t*-test (* $p \leq 0.05$).

2.3. Verbascoside Protected C2C12 Myoblasts and Myotubes from H₂O₂-Induced Reactive Oxygen Species

It has been reported that oxidative stress reduces the spare respiratory capacity (SRC), probably by chemically modifying and damaging some of the proteins involved in the electron transport chain [9]. Therefore, to evaluate the ability of verbascoside to counteract oxidative damage, we pre-treated C2C12 myoblasts and myotubes with increasing concentrations of verbascoside for 24 h and thereafter we exposed the cells to 1 mM H₂O₂ for 1 h

(myoblasts) and 2.5 h (myotubes) and tested their viability through a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. As shown in Figure 4A,B, 150 μM verbascoside was able to attenuate the cytotoxic effect induced by H_2O_2 ; indeed, in control myoblasts, exposure to H_2O_2 reduced cell viability to 69%, whereas 150 μM verbascoside restored it to 88%. In myotubes, the protective effect was statistically significant also at 75 μM verbascoside (Figure 4B). In particular, the exposure of control myotubes to H_2O_2 lowered cell viability to 16%, while 75 μM and 150 μM verbascoside restored cell viability to 38% and 44%, respectively. The ability of verbascoside to counteract the production of H_2O_2 -induced reactive oxygen species (ROS) was confirmed by a 2',7'-dichlorofluorescein diacetate (DCF-DA) assay carried out on C2C12 myoblasts and myotubes, pre-treated with increasing concentrations of verbascoside for 24 h. After the addition of DCF-DA, cells were exposed to 1 mM H_2O_2 and the fluorescence induced by ROS production was recorded every 15 min. Figure 4C,D show that the anti-ROS activity elicited by verbascoside treatment followed a dose-dependent trend and reached statistical significance at concentration values of 150 μM for myoblasts (Figure 4C) and 75 μM for myotubes (Figure 4D). It is noteworthy that 150 μM verbascoside also reduced the formation of endogenous ROS in myoblasts and myotubes (Figure 4C,D).

2.4. Verbasco-side Reduced Oxidative Damage by Activating the Nrf2/HO-1 Axis

Nuclear factor erythroid 2-related factor (Nrf2) is a transcription factor that modulates the cellular response against oxidative stress, by inducing the expression of various enzymes with antioxidant activity. We evaluated whether verbascoside stimulated the cellular antioxidant system by regulating the expression levels of Nrf2. Western blotting experiments revealed that 150 μM verbascoside was able to increase the Nrf2 protein levels under oxidative conditions, in both C2C12 myoblasts and myotubes (Figure 5A,B,E,F). Under normal conditions, Nrf2 is maintained in the cytosol by interaction with Keap1, which mediates the ubiquitination-dependent proteasomal degradation of Nrf2. Under oxidative stress, some cysteines of Keap1 undergo chemical modifications, inducing a change in its conformation, which weakens the interaction between Nrf2 and Keap1. Nrf2 escapes the inhibition of Keap1 and moves to the nucleus, where it promotes the transcription of its target genes [23]. In order to verify whether the increased amount of Nrf2 protein was due to its reduced proteasomal degradation, we examined the extent of Nrf2 phosphorylation at serine 40. Indeed, it has been shown that *t*-butylhydroquinone, an antioxidant molecule, promotes the PKC-induced phosphorylation of serine 40, which liberates Nrf2 from Keap1 inhibition [24]. Figure 5C,D shows that 150 μM verbascoside increased the proportion of Nrf2 protein carrying phosphorylation at serine 40 (p-Nrf2) under oxidative stress, although this effect reached statistical significance only in myoblasts, corroborating the Nrf2 protein expression profile.




Figure 4. Cont.




Figure 4. Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tests. C2C12 myoblasts (A) and myotubes (B) pre-treated with increasing concentrations of verbascoside for 24 h were exposed to 1 mM H₂O₂ for 1h (myoblasts) and 2.5 h (myotubes). Data are reported as mean percentage values \pm SD relative to control (100%) of three independent experiments performed in duplicate. Statistical analysis was carried out using Student's *t*-test (* $p \leq 0.05$, *** $p \leq 0.001$ H₂O₂-treated cells vs. untreated cells at the same concentration of verbascoside; §§ $p \leq 0.01$, §§§ $p \leq 0.001$ verbascoside and H₂O₂-treated cells vs. H₂O₂-treated cells). Intracellular reactive oxygen species (ROS) induce oxidation of 2',7'-dichlorofluorescein, resulting in a fluorescent compound

whose concentration is directly proportional to the amount of ROS. C2C12 myoblasts (C) and myotubes (D) were pre-treated with increasing concentrations of verbascoside and exposed to 1 mM H₂O₂. Fluorescence intensity is expressed in arbitrary units (A.U.) and reported as average values \pm SD from three independent experiments performed in duplicate. Statistical analysis was carried out using Student's *t*-test (** $p \leq 0.01$, *** $p \leq 0.001$, H₂O₂-treated cells vs. untreated cells at the same concentration of verbascoside; § $p \leq 0.05$, §§ $p \leq 0.01$, verbascoside and H₂O₂-treated cells vs. H₂O₂-treated cells; # $p \leq 0.05$, verbascoside-treated cells vs. untreated cells).




Figure 5. Cont.




Figure 5. Cont.




Figure 5. Pre-treatment of cells with 150 μ M verbascoside for 24 h, followed by exposure to 0.5 mM H₂O₂ for 1 h, increased the expression levels of nuclear factor erythroid 2-related factor (Nrf2) in C2C12 myoblasts (A) and myotubes (B) and the p-Nrf2/Nrf2 ratio in C2C12 myoblasts (C) and myotubes (D). Data are expressed as the mean percentage relative to untreated cells (control 100%) \pm SD of at least three independent experiments. Differences between mean values were assessed by Student's *t*-test (* $p \leq 0.05$, ** $p \leq 0.01$, verbascoside-treated vs. untreated cells under oxidative conditions; § $p \leq 0.05$, §§§ $p \leq 0.001$ verbascoside and H₂O₂-treated cells vs. untreated cells). Representative Western blotting experiments showing protein expression levels of Nrf2 and p-Nrf2 in C2C12 myoblasts (E) and myotubes (F). Tubulin was used as a loading control.

Since the phosphorylation of serine 40 has no effect on Nrf2 translocation into the nucleus or its activity as a transcription factor [24], we evaluated verbascoside/H₂O₂-induced Nrf2 nuclear translocation by confocal fluorescence microscopy. The collected confocal images showed a significant change in the localization pattern of Nrf2 among control untreated cells and verbascoside-treated cells. Namely, in control myoblasts and myotubes, Nrf2 displayed a faint and diffuse signal throughout the cytoplasm and the nucleus. After treatment with 150 μ M verbascoside for 24 h under non-oxidative conditions or with 0.5 mM H₂O₂ for 1 h, Nrf2 was less disperse and predominantly localized at the perinuclear and nuclear regions, as can be observed in Figure 6A for myoblasts and in Figure 6B for myotubes. In myoblasts exposed to oxidative conditions, pre-treatment with 150 μ M verbascoside induced the relevant nuclear translocation of the transcription factor within the nucleus, where the Nrf2 signal was mainly localized, clearly indicating its possible activation (Figure 6A). In myotubes pre-treated with 150 μ M verbascoside and exposed to oxidative conditions, the Nrf2 signal was increased in all cellular compartments compared to the control, but its distribution remained uniform throughout the cytoplasm and the nucleus (Figure 6B).

To further investigate the role played by verbascoside in the activation of Nrf2, we analyzed the transcription levels of heme oxygenase 1 (HO-1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α), which are two known Nrf2 target genes. An increase in the transcriptional levels of HO-1 and PGC-1 α was induced by treating C2C12 myoblasts with 150 μ M verbascoside for 24 h, under both normal and oxidative conditions (Figure 7A,C). In C2C12 myotubes, similar results were obtained for the HO-1 transcription levels (Figure 7B), in line with the protection that verbascoside offered not only against H₂O₂-induced but even against the endogenous ones. Conversely, the PGC-1 α transcription levels were unaffected by verbascoside in C2C12 myotubes (Figure 7D). This could be explained considering that the measurement of mRNA levels was performed on C2C12 cells at the fifth day of differentiation, when the transcription of PGC-1 α had already reached its maximum level (Figure S1).




Figure 6. Cont.




Figure 6. Representative confocal immunofluorescence images of C2C12 myoblasts (A) and myotubes (B) treated with 150 μM verbasicoside for 24 h, exposed to 0.5 mM H_2O_2 for 1 h or exposed to 0.5 mM H_2O_2 for 1 h after treatment with 150 μM verbasicoside for 24 h. Fluorescence intensity scans (panels on the right) along the white bar reported in the merged and zoomed images were acquired using the ROI Manager tool ($n = 50$). Nuclear factor erythroid 2-related factor (Nrf2) signal in red, nucleus in blue (scale bar 20 μm).




Figure 7. Cont.




Figure 7. Pre-treatment of cells with 150 μ M verbascoside for 24 h increased the transcription levels of heme oxygenase-1 (HO-1) in C2C12 myoblasts (A) and myotubes (B) and of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α) in C2C12 myoblasts (C) but not in myotubes (D), under both oxidative and non-oxidative conditions. mRNA levels were evaluated by Real-Time PCR and are expressed as the mean percentage relative to untreated cells (control 100%) \pm SD of three independent experiments run in triplicate. Differences between mean values were assessed by Student's *t*-test (* $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, verbascoside-treated cells vs. untreated cells; § $p \leq 0.05$, §§ $p \leq 0.01$, §§§ $p \leq 0.001$ verbascoside and H_2O_2 -treated cells vs. untreated cells).

3. Discussion

There is an ever-growing number of studies revealing that mitochondrial dysfunction represents a hallmark of many muscular pathologies. Altered mitochondrial structure and function have been observed in induced pluripotent stem cell-derived cardiomyocytes from patients affected by Duchenne muscular dystrophy, an X-linked disease caused by the loss of the dystrophin gene [25]. Interestingly, an abnormal mitochondrial ultrastructure can be observed before the onset of muscle fiber damage in mdx mice, which are a commonly used animal model of Duchenne muscular dystrophy [26,27]. Reduced mitochondrial function has been reported in both myoblasts and myotubes from patients affected by a severe form of congenital muscular dystrophy due to laminin $\alpha 2$ deficiency (MDC1A). Notably, the mitochondrial dysfunction is accompanied by a significant reduction in the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α), which plays a crucial role in mitochondrial biogenesis [8]. Mitochondrial impairment also characterizes the muscle tissue of patients affected by Huntington's disease, a neurodegenerative disorder, whose neurological symptoms often include muscle atrophy [28]. Additionally, in this pathological condition, mitochondrial dysfunction, which can be observed at the very early stages of disease progression, is associated with PGC-1 α downregulation [29,30]. Moreover, the accumulation of dysfunctional mitochondria has been proven to significantly contribute to the progressive loss of skeletal muscle mass and strength observed during aging [31]. Given the important contribution of mitochondrial dysfunction to the etiology of a broad range of physio-pathological conditions, the preservation of proper mitochondrial function represents a promising strategy with positive repercussions in several therapeutic areas.

The measurement of the oxygen consumption rate (OCR) is very useful in assessing the functional properties of mitochondria. In this study, we employed the high-resolution respiratory (HRR) measurement technique, in order to evaluate the effects of verbascoside on the mitochondrial respiratory parameters of skeletal muscle cells. HRR measurements were performed on intact C2C12 myoblasts and myotubes under physiological substrate supply by using a coupling control protocol [32], which allows one to evaluate respiratory function without the addition of exogenous substrates and ADP. This method has proven to be particularly suitable for preserving all mitochondrial perturbations affecting cellular respiration [22,32–34]. The comparison of the OCR of verbascoside-treated C2C12 myoblasts and myotubes with that of untreated cells revealed, for the first time, that verbascoside increases the maximal OCR of cells and their spare respiratory capacity (SRC), a respiratory parameter, which quantifies the mitochondrial ability to meet a sudden demand for additional energy. Indeed, recent evidence shows that the SRC can be viewed as a marker of mitochondrial fitness, in all organs or tissues requiring a large amount of energy, such as the heart, brain and skeletal muscle. Cells with higher SRC capacity seem to have higher adaptability to stress conditions as compared to cells with low SRC levels [9]. Our results show that verbascoside is also able to partially restore the loss of maximal OCR and SRC displayed by cells subjected to H₂O₂-induced oxidative stress (see Tables 1 and 2). This may contribute to explaining the anti-fatigue action of verbascoside found in other studies [18–20].

Many factors contribute to the maintenance of the SRC, such as the availability of mitochondrial substrates produced by the metabolism of nutrients. The mitochondrial homeostasis also plays a crucial role in supporting SRC; for instance, PGC-1 α -induced mitochondrial biogenesis has been found to be associated with high SRC values [35], whereas aberrations in PINK/PARKIN-dependent mitophagy, a process aimed at the removal of damaged mitochondria, resulted in lower SRC values [36–38]. Interestingly, Zhang and colleagues have recently demonstrated that verbascoside exerts its anti-fatigue activity by promoting mitophagy in an animal model of cachexia [20]. Oxidative stress is another key element that influences mitochondrial integrity and may strongly reduce the SRC values [9]. In our study, verbascoside triggered the nuclear translocation of the nuclear factor erythroid 2-related factor (Nrf2) and the upregulation of its target gene, heme

oxygenase-1 (HO-1), thus stimulating an important cellular response against oxidative stress. In myoblasts, but not in myotubes, verbascoside also increased the transcriptional levels of PGC-1 α . This suggests that, in myoblasts, verbascoside might elicit an antioxidant effect by activating the PGC-1 α /Nrf2/HO-1 signaling pathway. It is noteworthy that the interplay between Nrf2 and PGC-1 α generates a loop stimulating a cellular response against oxidative stress [39]. A possible explanation for the lack of PGC-1 α modulation in myotubes might arise by observing that, on the fifth day of cell differentiation, when we must harvest cells to extract mRNA, the transcription of PGC-1 α had already reached its maximum level, making it difficult to observe further increments (see Figure S1). In the future, it would be interesting to verify whether verbascoside is capable of upregulating PGC-1 α in all the pathological conditions in which it is downregulated. Indeed, since it plays a crucial role in mitochondrial biogenesis, any genetic or pharmacological increase in PGC-1 α has been proven to restore the normal phenotype in injured mdx mice [40,41] or in HD patients [29].

Our findings are in accordance with previous studies showing that verbascoside is able to preserve mitochondrial membrane potential in different neuronal cell models (i.e., in SH-SY5Y [42], PC12 [43] or primary rat cortical cells [44]), exposed to different drug-induced injuries. Similarly to what we observed, it was proposed that the protective role elicited by verbascoside on A β -treated PC12 cells was essentially based on the Nrf2 activation and consequent HO-1 induction [45]. Verbascoide was found to activate Nrf2 also in TNF α -treated A549 lung cells [46], in the neuronal tissue of a zebrafish model of Parkinson's disease [47], in UV-treated HaCaT keratinocytes [48] and in retinal pigment epithelial cells exposed to high glucose [49].

The protective role of verbascoside against oxidative stress presumably predisposes myoblasts to better regenerative performance. Indeed, the excessive production of ROS leads to apoptosis and inhibits muscle satellite cells' proliferation [50], whereas counteracting the oxidative stress—for example, by the genetic or pharmacological activation of HO-1—improves the viability and proliferation of myoblasts [51,52]. The increase in the SRC induced by verbascoside treatment might have similar beneficial repercussions, since the differentiation of myoblasts into mature myotubes is accompanied by a metabolic shift from glycolysis to oxidative phosphorylation and strictly depends on mitochondrial function and activity [53–56]. The stimulation of regenerative processes represents an important therapeutical strategy in many pathological conditions. Indeed, regeneration processes are particularly intense in dystrophic muscles, where they compensate for damage induced by genetic defects, like the loss of dystrophin in Duchenne muscular dystrophy or laminin α 2 in MDC1A, but also in muscles undergoing continuous cycles of contraction and relaxation, during intense physical activity.

An interesting possible translational outcome of our study would be to test the use of verbascoside in combination with already consolidated drugs to alleviate the symptoms of muscular dystrophy or other neuromuscular disorders, exploiting available animal models (mdx, myd, dy or others) or even small cohorts of patients.

4. Materials and Methods

4.1. Cell Culture

The mouse C2C12 myoblast cell line was cultured in growth medium consisting of Dulbecco's Modified Eagle Medium (DMEM-41966, high glucose, pyruvate, phenol red; Gibco, Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Paisley, UK), 10 mg/mL penicillin (Sigma–Aldrich, St. Louis, MO, USA) and 10 mg/mL streptomycin (Sigma–Aldrich) and incubated at 37 °C in humidified air with 5% CO₂. At confluence, myoblasts were induced to differentiate with DMEM supplemented with 5% horse serum (HS; Gibco), 10 mg/mL penicillin (Sigma–Aldrich) and 10 mg/mL streptomycin (Sigma–Aldrich). At days 1, 2, 3, 5 and 7 of differentiation, cells were collected and stored at 80 °C until total RNA isolation. For all experiments, cell lines with passage numbers between 9 and 15 were used.

4.2. Cell Viability

C2C12 myoblasts and myotubes were treated with verbasoside (Extrasynthesis, Grenoble, France) at different concentration values ranging between 19 and 500 μM . After 24 h of incubation, control cells and cells treated with increasing concentrations of verbasoside were rinsed twice with serum-free DMEM and then further combined with 1 mM H_2O_2 in serum-free DMEM for 1 h (myoblasts) or 2.5 h (myotubes) at 37 °C in humidified air with 5% CO_2 . At the end of the experiments, cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. Cell cultures were incubated with 0.5 mg/mL MTT reagent, which was transformed into formazan crystals after about 4 h of incubation at 37 °C. The intracellular crystals were solubilized with a solution of 0.04 M HCl in isopropanol. The amount of formazan released into the culture supernatant, which was directly proportional to the number of living cells, was measured using an automatic microplate photometer (PackardSpectracount™, Packard BioScience Company, Meriden, CT, USA) at a wavelength of 562 nm [57]. Each experiment was performed in duplicate and repeated three times; the cell cytotoxicity was calculated according to the following equation:

$$\% \text{ cell viability} = (\text{Sample OD}/\text{Control OD}) \times 100$$

4.3. High-Resolution Respirometry

Respiration in intact C2C12 myoblasts and myotubes was monitored with high-resolution respirometry (Oroboros Oxygraph-2k, Innsbruck, Austria) operating at 37 °C with a 2 mL chamber volume [58]. Cellular respiration experiments were carried out in two O2k chambers operated in parallel after calibration of the oxygen sensors at air saturation and instrumental background correction. Calibration with air-saturated medium was performed immediately before the oxygen flux measurement was taken. The data acquisition and analysis were carried out using the software DatLab, version 4.2 (Oroboros Instruments).

On the day of measurement, C2C12 myoblasts and myotubes, pre-treated with 150 μM verbasoside or vehicle for 24 h, were incubated in serum-free DMEM containing 0.5 mM H_2O_2 for 1 h at 37 °C in humidified air with 5% CO_2 . Before the experiment, cells were trypsinized, counted, resuspended in their medium to a final concentration of 1×10^6 cells/mL, added to each Oxygraph chamber (chamber A and chamber B) and thereafter investigated using a phosphorylation control protocol [54]. The experiments began with the measurement of the basal oxygen consumption rate (OCR) (i.e., the respiration of drug-treated cells resuspended in the medium without the addition of substrates), followed for about 10 min, until a steady-state level was obtained (basal OCR). ATP synthase was inhibited by the addition of oligomycin (2 $\mu\text{g}/\text{mL}$) added to each chamber to detect the OCR from proton leak. The maximal respiration capacity (maximal OCR) was obtained by the addition of small volumes of the uncoupler carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 0.25 μM FCCP/step) and the instantaneous observation of its effect on cellular respiration in the uncoupled state. Cell respiration was then measured in the presence of 0.5 μM rotenone, which selectively inhibits CI, and then in the presence of 2.5 μM antimycin A, which inhibits CIII, to estimate the residual OCR. In addition to the instrumental background, the mitochondrial respiration was corrected for the oxygen flux due to residual OCR [58]. Oligomycin-sensitive respiration (ATP-linked OCR) was calculated by subtracting the oligomycin-insensitive respiration rate from basal respiration (basal OCR–proton leak OCR). All inhibitors and uncouplers used in the protocol are able to cross the cell membrane and do not require prior cell permeabilization. The derived respiratory parameters were calculated as follows: assuming that state 3 respiration is equivalent to the rate measured after the addition of FCCP ('state 3_{FCCP}' or 'state 3u') and state 4 is the rate measured after the addition of oligomycin ('state 4_{oligomycin}' or 'state 4o'), the uncoupled respiratory control ratio (RCR) was calculated by dividing the state 3u rate by the state 4o rate (maximal OCR/proton leak OCR) [59]. The spare respiratory

capacity (SRC) was derived by calculating the ratio between the maximal capacity of the electron transport system and the basal OCR (maximal OCR/basal OCR). The coupling efficiency (CE), which represents the proportion of mitochondrial oxygen consumption used to synthesize ATP, was calculated by dividing the oligomycin-sensitive respiration rate by the basal OCR (ATP-linked OCR/basal OCR) [22]. Each experiment was carried out in duplicate and repeated four times.

4.4. Detection of Reactive Oxygen Species

The production of intracellular reactive oxygen species (ROS) was evaluated using a 2',7'-dichlorofluorescein diacetate (DCF-DA)–cellular ROS detection assay kit (Abcam, Cambridge, UK). Briefly, C2C12 myoblasts and myotubes were treated with increasing concentrations of verbascoside, ranging from 19 μM to 150 μM , for 24 h. According to the manufacturer's instructions, after the addition of DCF-DA, cells were treated with PBS containing 1 mM H_2O_2 . DCF-DA is initially a non-fluorescent compound, which is deacetylated by cellular esterases to a non-fluorescent compound and later oxidized by ROS into 2',7'-dichlorofluorescein (DCF), a highly fluorescent compound. Fluorescence was quantified every 15 min for 1 h, after the addition of 1 mM H_2O_2 in PBS, using a multi-well plate reader (Promega, Madison, WI, USA), at excitation/emission 485/535 nm. ROS production was expressed as the fluorescence intensity. Each experiment, performed in duplicate, was repeated three times.

4.5. Protein Extraction and Western Blotting Analysis

C2C12 myoblasts and myotubes, pre-treated with 150 μM verbascoside or vehicle for 24 h, were incubated in serum-free DMEM containing 0.5 mM H_2O_2 for 1 h at 37 °C in humidified air with 5% CO_2 . Subsequently, cells were scraped in cold PBS buffer, centrifuged at 1000 rpm for 5 min and resuspended in lysis buffer (150 mM NaCl, 1% Triton X-100, 50 mM Tris HCl pH 8.0) containing protease and phosphatase inhibitors (Roche, Basel, Switzerland). Protein concentrations were measured by the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Samples were denatured in SDS–PAGE sample buffer for 5 min at 99 °C, loaded onto a 10% SDS PAGE gel (BioRad) and transferred to a PVDF membrane. After transfer, the membrane was blocked for 2 h at room temperature with 3% BSA (Sigma–Aldrich) in TBS containing 0.1% Tween 20 (Sigma–Aldrich). PVDF membranes were probed with rabbit polyclonal anti-Nrf2 (1:1000, #16396-1-AP, Proteintech, Planegg-Martinsried, Germany), rabbit polyclonal anti-phospho-Nrf2 (Ser 40) (1:1000, #PA5-67520, Invitrogen, Waltham, MA, USA) or anti-tubulin-HRP (1:1000, sc-23949, Santa Cruz, CA, USA), as tubulin was used as a loading control protein. Signals were captured with an Alliance Q9-atom manual imaging system (Uvitec, Cambridge, UK), using an enhanced chemiluminescence system. Densitometric analyses were carried out with the software Nine-Alliance, version 9.7 (Uvitec). Each experiment was repeated three times.

4.6. RNA Isolation and RT-PCR

Before RNA extraction, C2C12 myoblasts and myotubes were pre-treated with 150 μM verbascoside or vehicle for 24 h and then incubated in serum-free DMEM containing 0.5 mM H_2O_2 for 1 h at 37 °C in humidified air with 5% CO_2 . Total RNA was isolated from C2C12 myoblasts and myotubes using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. An additional on-column DNase treatment was performed to remove residual DNA. Then, 1 μg of total RNA was reverse-transcribed in a 20 μL reaction mixture using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), following the manufacturer's instructions. Quantitative Real-Time PCR was performed using a standard TaqMan[®] PCR protocol on a StepOne Real-Time PCR System (Applied Biosystems) with probes specific for murine heme oxygenase 1 (HO-1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α). The housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT) was used as a reference. The reactants were incubated at 50 °C for 2 min and 95 °C for

10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. All reactions were run in triplicate. The relative level for each gene was calculated using the $2^{-\Delta\Delta CT}$ method [60] and reported as a fold change percentage. Each experiment was performed in triplicate and repeated three times.

4.7. Immunofluorescence

C2C12 myoblasts and myotubes, pre-treated with 150 μ M verbascoside or vehicle for 24 h, were incubated in serum-free DMEM containing 0.5 mM H₂O₂ for 1 h at 37 °C in humidified air with 5% CO₂. Subsequently, cells were fixed with 4% paraformaldehyde for 10 min at room temperature. Non-specific sites were blocked with 1% BSA in TBS containing 1% Triton X-100. Cells were incubated with the anti-Nrf2 polyclonal antibody (1:50, #16396-1-AP, Proteintech, Germany) for 1 h. Cells were washed with TBS and then incubated with an anti-rabbit secondary antibody conjugated with rhodamine (1:500, ThermoFisher, Waltham, MA, USA) and imaged with a confocal laser scanning system (A1+, Nikon, Tokyo, Japan) using laser excitation at 562 nm to collect emission signals from rhodamine. DAPI staining was used to visualize nuclei [61]. Analysis of images was carried out using the software ImageJ, version 2.9.0. Fluorescence intensity analysis of 50 cells at the same focus plane was performed along the same distance by the ROI Manager tool.

4.8. Statistical Analysis

Data are presented as mean values \pm standard deviation (SD). Student's *t*-test was used throughout this study for statistical analyses, assuming equal variance. *p*-values were calculated based on the 2-tailed test; a *p* value < 0.05 was considered statistically significant. Statistical analysis was performed with the software GraphPad Prism, version 8.0.2.

5. Conclusions

In conclusion, we found, for the first time, that verbascoside enhanced the maximal oxygen consumption rate and mitochondrial spare respiratory capacity in murine myoblasts and myotubes. Furthermore, our data suggest that the verbascoside-induced activation of the Nrf2/HO-1 axis might be related to the observed reduction in endogenous and H₂O₂-induced ROS levels and increased cell viability under oxidative stress conditions. The cytoprotective activity of verbascoside against oxidative stress could thus contribute to improving mitochondrial function. Our findings suggest a novel mechanism underlying the beneficial effects elicited by verbascoside, which include anti-fatigue action. Further work will be necessary to investigate in more detail the specific molecular mechanism behind verbascoside's action. The results here presented, in fact, do not rule out the possible presence of alternative metabolic or genetic pathways, yet unidentified, also responsible for the protective effect exerted by verbascoside in skeletal muscle cells.

Supplementary Materials: The supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms242015276/s1>.

Author Contributions: Conceptualization, M.B. and F.S.; Methodology, F.S., P.B. and M.B.; Validation, F.S., P.B. and M.B.; Formal Analysis, F.S., P.B. and M.B.; Investigation, P.B., F.S. and M.B.; Data Curation, P.B., F.S. and M.B.; Writing—Original Draft Preparation, M.B.; Writing—Review and Editing, M.B., F.S., A.B. (Andrea Brancaccio), M.D.L. and A.B. (Alessandra Braca); Visualization, P.B., F.S. and M.B.; Funding Acquisition, M.B. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Fondi di Ateneo, UCSC Rome, Italy (Linea D1, 2018, R4124500660 to M.B.).

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: The authors thank Maria Giulia Bigotti (University of Bristol, UK) for the critical reading of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Barbieri, E.; Sestili, P. Reactive oxygen species in skeletal muscle signalling. *J. Signal Transduct.* **2012**, *2012*, 982794. [[CrossRef](#)] [[PubMed](#)]
2. Suzuki, T.; Yamamoto, M. Molecular Basis of the Keap1-Nrf2 System. *Free Radic. Biol. Med.* **2015**, *88*, 93–100. [[CrossRef](#)]
3. Suzuki, T.; Yamamoto, M. Stress-Sensing Mechanisms and the Physiological Roles of the Keap1-Nrf2 System during Cellular Stress. *J. Biol. Chem.* **2017**, *292*, 16817–16824. [[CrossRef](#)]
4. Jitcă, G.; Ōsz, B.E.; Tero-Vescan, A.; Miklos, A.P.; Ruzs, C.M.; Bătrînu, M.G.; Vari, C.E. Positive Aspects of Oxidative Stress at Different Levels of the Human Body: A Review. *Antioxidants* **2022**, *11*, 572. [[CrossRef](#)] [[PubMed](#)]
5. Amorim, J.A.; Sinclair, D.A. Measuring PGC-1 α and Its Acetylation Status in Mouse Primary Myotubes. *Methods Mol. Biol.* **2021**, *2310*, 301–309. [[PubMed](#)]
6. Bellissimo, C.A.; Garibotti, M.C.; Perry, C.G.R. Mitochondrial stress responses in Duchenne muscular dystrophy: Metabolic dysfunction or adaptive reprogramming? *Am. J. Physiol. Cell Physiol.* **2022**, *323*, C718–C730. [[CrossRef](#)]
7. Bernardi, P.; Bonaldo, P. Mitochondrial dysfunction and defective autophagy in the pathogenesis of collagen VI muscular dystrophies. *Cold Spring Harb. Perspect. Biol.* **2013**, *5*, a011387. [[CrossRef](#)]
8. Fontes-Oliveira, C.C.; Steinz, M.; Schneiderat, P.; Mulder, H.; Durbeej, M. Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells. *Sci. Rep.* **2017**, *7*, 45272. [[CrossRef](#)]
9. Marchetti, P.; Fovez, Q.; Germain, N.; Khamari, R.; Kluza, J. Mitochondrial spare respiratory capacity: Mechanisms, regulation, and significance in non-transformed and cancer cells. *FASEB J.* **2020**, *34*, 13106–13124. [[CrossRef](#)]
10. Schuh, R.A.; Jackson, K.C.; Khairallah, R.J.; Ward, C.W.; Spangenburg, E.E. Measuring mitochondrial respiration in intact single muscle fibers. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2012**, *302*, R712–9. [[CrossRef](#)]
11. Timpani, C.A.; Hayes, A.; Rybalka, E. Revisiting the dystrophin-ATP connection: How half a century of research still implicates mitochondrial dysfunction in Duchenne Muscular Dystrophy aetiology. *Med. Hypotheses* **2015**, *85*, 1021–1033. [[CrossRef](#)]
12. Desler, C.; Hansen, T.L.; Frederiksen, J.B.; Marcker, M.L.; Singh, K.K.; Rasmussen, L.J. Is There a Link between Mitochondrial Reserve Respiratory Capacity and Aging? *J. Aging Res.* **2012**, *2012*, 192503. [[CrossRef](#)] [[PubMed](#)]
13. Ryu, D.; Zhang, H.; Ropelle, E.R.; Sorrentino, V.; Mázala, D.A.; Mouchiroud, L.; Marshall, P.L.; Campbell, M.D.; Ali, A.S.; Knowels, G.M.; et al. NAD⁺ repletion improves muscle function in muscular dystrophy and counters global PARylation. *Sci. Transl. Med.* **2016**, *8*, 361ra139. [[CrossRef](#)] [[PubMed](#)]
14. Mohiuddin, M.; Lee, N.H.; Moon, J.Y.; Han, W.M.; Anderson, S.E.; Choi, J.J.; Shin, E.; Nakhai, S.A.; Tran, T.; Aliya, B.; et al. Critical Limb Ischemia Induces Remodeling of Skeletal Muscle Motor Unit, Myonuclear and Mitochondrial-Domains. *Sci. Rep.* **2019**, *9*, 9551. [[CrossRef](#)]
15. Galli, A.; Marciari, P.; Marku, A.; Ghislanzoni, S.; Bertuzzi, F.; Rossi, R.; Di Giancamillo, A.; Castagna, M.; Perego, C. Verbascoside Protects Pancreatic β -Cells against ER-Stress. *Biomedicines* **2020**, *8*, 582. [[CrossRef](#)]
16. Treml, J.; Večeřová, P.; Herczogová, P.; Šmejkal, K. Direct and Indirect Antioxidant Effects of Selected Plant Phenolics in Cell-Based Assays. *Molecules* **2021**, *26*, 2534. [[CrossRef](#)] [[PubMed](#)]
17. Canovai, A.; Amato, R.; Melecchi, A.; Dal Monte, M.; Rusciano, D.; Bagnoli, P.; Cammalleri, M. Preventive Efficacy of an Antioxidant Compound on Blood Retinal Barrier Breakdown and Visual Dysfunction in Streptozotocin-Induced Diabetic Rats. *Front. Pharmacol.* **2022**, *12*, 811818. [[CrossRef](#)]
18. Liao, F.; Zheng, R.L.; Gao, J.J.; Jia, Z.J. Retardation of skeletal muscle fatigue by the two phenylpropanoid glycosides: Verbascoside and martynoside from *Pedicularis plicata* maxim. *Phytother. Res.* **1999**, *13*, 621–623. [[CrossRef](#)]
19. Zhu, M.; Zhu, H.; Tan, N.; Wang, H.; Chu, H.; Zhang, C. Central anti-fatigue activity of Verbascoside. *Neurosci. Lett.* **2016**, *616*, 75–79. [[CrossRef](#)]
20. Zhang, S.; Gong, F.; Liu, J.; Liu, T.; Yang, J.; Hu, J. A novel PHD2 inhibitor acteoside from *Cistanche tubulosa* induces skeletal muscle mitophagy to improve cancer-related fatigue. *Biomed. Pharmacother.* **2022**, *150*, 113004. [[CrossRef](#)]
21. D’Imperio, M.; Cardinali, A.; D’Antuono, I.; Linsalata, V.; Minervini, F.; Redan, B.W.; Ferruzzi, M.G. Stability–activity of verbascoside, a known antioxidant compound, at different pH conditions. *Food Res. Int.* **2014**, *66*, 373–378. [[CrossRef](#)]
22. Brand, M.D.; Nicholls, D.G. Assessing mitochondrial dysfunction in cells. *Biochem. J.* **2011**, *435*, 297–312. [[CrossRef](#)]
23. Liu, T.; Lv, Y.F.; Zhao, J.L.; You, Q.D.; Jiang, Z.Y. Regulation of Nrf2 by phosphorylation: Consequences for biological function and therapeutic implications. *Free Radic. Biol. Med.* **2021**, *168*, 129–141. [[CrossRef](#)] [[PubMed](#)]
24. Bloom, D.A.; Jaiswal, A.K. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. *J. Biol. Chem.* **2003**, *278*, 44675–44682. [[PubMed](#)]
25. Willi, L.; Abramovich, I.; Fernandez-Garcia, J.; Agranovich, B.; Shulman, M.; Milman, H.; Baskin, P.; Eisen, B.; Michele, D.E.; Arad, M.; et al. Bioenergetic and Metabolic Impairments in Induced Pluripotent Stem Cell-Derived Cardiomyocytes Generated from Duchenne Muscular Dystrophy Patients. *Int. J. Mol. Sci.* **2022**, *23*, 9808. [[CrossRef](#)]

26. Vila, M.C.; Rayavarapu, S.; Hogarth, M.W.; Van der Meulen, J.H.; Horn, A.; Defour, A.; Takeda, S.; Brown, K.J.; Hathout, Y.; Nagaraju, K.; et al. Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy. *Cell Death Differ.* **2017**, *24*, 330–342. [[CrossRef](#)]
27. Moore, T.M.; Lin, A.J.; Strumwasser, A.R.; Cory, K.; Whitney, K.; Ho, T.; Ho, T.; Lee, J.L.; Rucker, D.H.; Nguyen, C.Q.; et al. Mitochondrial Dysfunction Is an Early Consequence of Partial or Complete Dystrophin Loss in *mdx* Mice. *Front. Physiol.* **2020**, *11*, 690. [[CrossRef](#)]
28. Bozzi, M.; Sciandra, F. Molecular Mechanisms Underlying Muscle Wasting in Huntington's Disease. *Int. J. Mol. Sci.* **2020**, *21*, 8314. [[CrossRef](#)]
29. Chaturvedi, R.K.; Adhietty, P.; Shukla, S.; Hennessy, T.; Calingasan, N.; Yang, L.; Starkov, A.; Kiaei, M.; Cannella, M.; Sassone, J.; et al. Impaired PGC-1 α function in muscle in Huntington's disease. *Hum. Mol. Genet.* **2009**, *18*, 3048–3065. [[CrossRef](#)]
30. Johri, A.; Calingasan, N.Y.; Hennessey, T.M.; Sharma, A.; Yang, L.; Wille, E.; Chandra, A.; Beal, M.F. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. *Hum. Mol. Genet.* **2012**, *21*, 1124–1137. [[CrossRef](#)]
31. Leduc-Gaudet, J.P.; Hussain, S.N.A.; Barreiro, E.; Gousspillou, G. Mitochondrial Dynamics and Mitophagy in Skeletal Muscle Health and Aging. *Int. J. Mol. Sci.* **2021**, *22*, 8179. [[CrossRef](#)]
32. Gnaiger, E. Mitochondrial Pathways and Respiratory Control. An Introduction to OXPHOS Analysis. In *Mitochondr Physiol Network 19.12*, 4th ed.; Oroboros MiPNet Publications: Innsbruck, Austria, 2014; p. 80.
33. Wallace, K.B. Mitochondrial off targets of drug therapy. *Trends Pharmacol. Sci.* **2008**, *29*, 361–366. [[CrossRef](#)] [[PubMed](#)]
34. Bottoni, P.; Pontoglio, A.; Scarà, S.; Pieroni, L.; Urbani, A.; Scatena, R. Mitochondrial Respiratory Complexes as Targets of Drugs: The PPAR Agonist Example. *Cells* **2022**, *11*, 1169. [[CrossRef](#)]
35. Vazquez, F.; Lim, J.-H.; Chim, H.; Bhalla, K.; Girnun, G.; Pierce, K.; Clish, C.B.; Granter, S.R.; Widlund, H.R.; Spiegelman, B.M.; et al. PGC1 α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. *Cancer Cell* **2013**, *23*, 287–301. [[CrossRef](#)]
36. Kashatus, J.A.; Nascimento, A.; Myers, L.J.; Sher, A.; Byrne, F.L.; Hoehn, K.L.; Counter, C.M.; Kashatus, D.F. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. *Mol. Cell* **2015**, *57*, 537–551. [[CrossRef](#)]
37. Stevens, D.A.; Lee, Y.; Kang, H.C.; Lee, B.D.; Lee, Y.I.; Bower, A.; Jiang, H.; Kang, S.U.; Andrabi, S.A.; Dawson, V.L.; et al. Parkin loss leads to PARIS dependent declines in mitochondrial mass and respiration. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 11696–11701. [[CrossRef](#)]
38. Costa, A.C.; Loh, S.H.Y.; Martins, L.M. Drosophila Trap1 protects against mitochondrial dysfunction in a PINK1/parkin model of Parkinson's disease. *Cell Death Dis.* **2019**, *4*, e467. [[CrossRef](#)]
39. Gureev, A.P.; Shaforostova, E.A.; Popov, V.N. Regulation of Mitochondrial Biogenesis as a Way for Active Longevity: Interaction Between the Nrf2 and PGC-1 α Signalling Pathways. *Front. Genet.* **2019**, *10*, 435. [[CrossRef](#)]
40. Selsby, J.T.; Morine, K.J.; Pendrak, K.; Barton, E.R.; Sweeney, H.L. Rescue of dystrophic skeletal muscle by PGC-1 α involves a fast to slow fiber type shift in the *mdx* mouse. *PLoS ONE* **2012**, *7*, e30063. [[CrossRef](#)]
41. Chan, M.C.; Rowe, G.C.; Raghuram, S.; Patten, I.S.; Farrell, C.; Arany, Z. Post-natal induction of PGC-1 α protects against severe muscle dystrophy independently of utrophin. *Skelet. Muscle* **2014**, *4*, 2. [[CrossRef](#)]
42. Wang, H.; Xu, Y.; Yan, J.; Zhao, X.; Sun, X.; Zhang, Y.; Guo, J.; Zhu, C. Acteoside protects human neuroblastoma SH-SY5Y cells against beta-amyloid-induced cell injury. *Brain Res.* **2009**, *1283*, 139–147. [[CrossRef](#)]
43. Sheng, G.Q.; Zhang, J.R.; Pu, X.P.; Ma, J.; Li, C.L. Protective effect of verbasoside on 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in PC12 cells. *Eur. J. Pharmacol.* **2002**, *451*, 119–124. [[CrossRef](#)]
44. Koo, K.A.; Kim, S.H.; Oh, T.H.; Kim, Y.C. Acteoside and its aglycones protect primary cultures of rat cortical cells from glutamate-induced excitotoxicity. *Life Sci.* **2006**, *79*, 709–716. [[CrossRef](#)] [[PubMed](#)]
45. Wang, H.Q.; Xu, Y.X.; Zhu, C.Q. Upregulation of heme oxygenase-1 by acteoside through ERK and PI3 K/Akt pathway confer neuroprotection against beta-amyloid-induced neurotoxicity. *Neurotox. Res.* **2012**, *21*, 368–378. [[CrossRef](#)] [[PubMed](#)]
46. Zheng, J.N.; Zhuo, J.Y.; Nie, J.; Liu, Y.L.; Chen, B.Y.; Wu, A.Z.; Li, Y.C. Phenylethanoid Glycosides from *Callicarpa kwangtungensis* Chun Attenuate TNF- α -Induced Cell Damage by Inhibiting NF- κ B Pathway and Enhancing Nrf2 Pathway in A549 Cells. *Front. Pharmacol.* **2021**, *12*, 693983. [[CrossRef](#)]
47. Li, M.; Zhou, F.; Xu, T.; Song, H.; Lu, B. Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signalling pathway. *Food Chem. Toxicol.* **2018**, *119*, 6–13. [[CrossRef](#)]
48. Gao, W.; Zheng, S.; Hwang, E.; Yi, T.H.; Wang, Y.S. Effects of phenylethanol glycosides from *Orobanchaceae cernua* Loeffling on UVB-Induced skin photodamage: A comparative study. *Photochem. Photobiol. Sci.* **2021**, *20*, 599–614. [[CrossRef](#)]
49. Yang, J.; Hua, Z.; Zheng, Z.; Ma, X.; Zhu, L.; Li, Y. Acteoside inhibits high glucose-induced oxidative stress injury in RPE cells and the outer retina through the Keap1/Nrf2/ARE pathway. *Exp. Eye Res.* **2023**, *232*, 109496. [[CrossRef](#)]
50. Urish, K.L.; Vella, J.B.; Okada, M.; Deasy, B.M.; Tobita, K.; Keller, B.B.; Cao, B.; Piganelli, J.D.; Huard, J. Antioxidant Levels Represent a Major Determinant in the Regenerative Capacity of Muscle Stem Cells. *Mol. Biol. Cell* **2009**, *20*, 509–520. [[CrossRef](#)]
51. Laumonier, T.; Yang, S.; König, S.; Chauveau, C.; Anegón, I.; Hoffmeyer, P.; Menetrey, J. Lentivirus Mediated HO-1 Gene Transfer Enhances Myogenic Precursor Cell Survival after Autologous Transplantation in Pig. *Mol. Ther.* **2008**, *16*, 404–410. [[CrossRef](#)]
52. Aggeli, I.-K.; Kefaloyianni, E.; Beis, I.; Gaitanaki, C. HOX-1 and COX-2: Two Differentially Regulated Key Mediators of Skeletal Myoblast Tolerance under Oxidative Stress. *Free Radic. Res.* **2010**, *44*, 679–693. [[CrossRef](#)] [[PubMed](#)]

53. Chung, S.; Dzeja, P.P.; Faustino, R.S.; Perez-Terzic, C.; Behfar, A.; Terzic, A. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. *Nat. Clin. Pract. Cardiovasc. Med.* **2007**, *4*, S60–S67. [[CrossRef](#)] [[PubMed](#)]
54. Chung, S.; Dzeja, P.P.; Faustino, R.S.; Terzic, A. Developmental restructuring of the creatine kinase system integrates mitochondrial energetics with stem cell cardiogenesis. *Ann. N. Y. Acad. Sci.* **2008**, *1147*, 254–263. [[CrossRef](#)]
55. Folmes, C.D.L.; Nelson, T.J.; Martinez-Fernandez, A.; Arrell, D.K.; Lindor, J.Z.; Dzeja, P.P.; Ikeda, Y.; Perez-Terzic, C.; Terzic, A. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. *Cell Metab.* **2011**, *14*, 264–271. [[CrossRef](#)]
56. Xu, D.; Jiang, Z.; Sun, Z.; Wang, L.; Zhao, G.; Hassan, H.M.; Fan, S.; Zhou, W.; Han, S.; Zhang, L.; et al. Mitochondrial dysfunction and inhibition of myoblast differentiation in mice with high-fat-diet-induced pre-diabetes. *J. Cell Physiol.* **2019**, *234*, 7510–7523. [[CrossRef](#)]
57. Marigo, L.; Spagnuolo, G.; Malara, F.; Martorana, G.E.; Cordaro, M.; Lupi, A.; Nocca, G. Relation between conversion degree and cytotoxicity of a flowable bulk-fill and three conventional flowable resin-composites. *Eur. Rev. Med. Pharmacol. Sci.* **2015**, *19*, 4469–4480.
58. Pesta, D.; Gnaiger, E. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. *Methods Mol. Biol.* **2012**, *810*, 25–58.
59. Dott, W.; Mistry, P.; Wright, J.; Cain, K.; Herbert, K.E. Modulation of mitochondrial bioenergetics in a skeletal muscle cell line model of mitochondrial toxicity. *Redox Biol.* **2014**, *2*, 224–233. [[CrossRef](#)]
60. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **2001**, *25*, 402–408. [[CrossRef](#)]
61. Palmieri, V.; Bozzi, M.; Signorino, G.; Papi, M.; De Spirito, M.; Brancaccio, A.; Maulucci, G.; Sciandra, F. α -Dystroglycan hypoglycosylation affects cell migration by influencing β -dystroglycan membrane clustering and filopodia length: A multiscale confocal microscopy analysis. *Biochim. Biophys. Acta Mol. Basis Dis.* **2017**, *1863*, 2182–2191. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.